Torsdag 14 Augusti | 00:53:21 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Magle Chemoswed

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Est. tid*
2026-02-27 08:30 Bokslutskommuniké 2025
2025-10-31 07:30 Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.
Magle Chemoswed Holding Reports Financial Results For Second Quarter 2025
2025-08-01 07:30:00

Magle Group announces its Q2 2025 results amid short-term macroeconomic challenges, highlighting underlying strategic progress despite a temporary setback in financial performance. The quarter was impacted by delayed high-value orders, raw material shortages, and non-recurring integration costs tied to the Group’s recent acquisitions.

Q1 2025 KEY INDICATORS

  • Revenues amounted to 52.4 MSEK (46.0)
  • EBITDA equaled -20.6 MSEK (5.3)
  • Operating profit (EBIT) is -29.0 MSEK (1.3)
  • Earnings per share SEK -1.35 (0.01) per share

” While the second quarter did not meet our expectations due to external pressures, these headwinds are temporary. We remain confident in our long-term strategy and continue to see strong demand across our technologies and services. Integration of our newly acquired units Magle Biopolymers and Magle Biopharma, is progressing and will strengthen our market position and capabilities.” says Justin Pierce, CEO

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-01 07:30 CEST.

Attachments

Q2 2025 Interim Report Final

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden